# Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

> **NCT00354913** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 21 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** hydroxyurea
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00354913
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2009-03
- **Final completion:** 2010-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-01-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354913, "Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00354913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*